Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

European equities climbed as investors grew more optimistic that the worst-case impacts from US tariffs could be averted and ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...

Portuguese grid operator REN said on Monday it had "no information" that the mass power outages that hit the Iberian ...

International Business Machines plans to invest $150 billion in the U.S. over the next five years as tariffs threaten to make international manufacturing more expensive. Germany's Merck agreed to ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

Find insight on Merck KGaA, ResMed and more in the latest Market Talks covering the Health Care sector.